Chehade, R. E. H., Nawfal, R., Semaan, K., Eid, M., Saad, E., Machaalani, M., Yekedüz, E., Steiner, C., Khatoun, W. D., Maj, D., Zarba, M., Wells, C., Pal, S. K., Suarez, C., Takemura, K., Li, H., Baca, S. C., Xie, W., Heng, D. Y. C., Choueiri, T. K. (2025). Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4556